Brought to you by 
Roche, Seaside collaborate on Fragile X and autism disorders; terminated
11 Sep 2014
Executive Summary
Seaside Therapeutics LLC (neurodevelopmental diseases caused by single-gene mutations) has exclusively licensed Roche patents related to metabotropic glutamate receptor subtype 5 (mGluR5) antagonists for brain development disorders. The Big Pharma also received an option on Seaside’s gamma-aminobutyric acid type B (GABA-B) agonist STX209 (arbaclofen), in Phase III for Fragile X syndrome (FXS) and Phase II for autism spectrum disorders (ASD).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com